Latest Industry Projects

Rafarma Pharmaceuticals, Inc. (RAFA) Enters Into New Production Contract for Para-Aminosalicylic Acid

projects

Rafarma Pharmaceuticals, Inc. (RAFA) Enters Into New Production Contract for Para-Aminosalicylic Acid Rafarma Pharmaceuticals, Inc. (OTC: RAFA) is pleased to announce that in June of this year the Company entered into a production agreement to manufacture Para-Aminosalicylic Acid (PAS) to be marketed and distributed by OOO “Advance Trading,” which is one of the leading distributors of PAS in Russia. According to data provided by DSM Group (one of the leading analysts of pharmaceutical market in Russia), the PAS market in Russian Federation in 2011 was more than 8.2 Billion USD. Advance Trading is currently responsible for approximately 20% of sales of PAS in the Russian Market. Working with Advanced Trading will allow Rafarma to increase production of PAS and to become one of the leading suppliers of this product to the Russian market. Dave Anderson, CEO of Rafarma Pharmaceuticals, stated, “This new contract is yet another expansion of Rafarma’s production capability, opening the door for more revenue.” About Rafarma Pharmaceuticals, Inc. (RAFA) Operating from a new 270,000 square-foot state-of-the-art manufacturing and distribution facility in Russia, Rafarma Pharmaceuticals produces generic antibiotics and specialty pharmaceuticals in addition to its own line of proprietary products that are approved by the Ministry of Health of Russian Federation. For the last three years, the Russian Government has been highly focused on bolstering the development of nation’s domestic pharmaceutical industry. Rafarma Pharmaceuticals’ mission is to work with the auspices of aggressive federal initiatives to fast-track the modernization of Russia’s pharmaceutical industry. For more information on Rafarma Pharmaceuticals, visit: http://RAFA.QualityStocks.net http://www.rafarma.us/rafarma-pharmaceuticals-inc-rafa-enters-into-new-production-contract-for-para-aminosalicylic-acid/ Project Name RAFA enters new production contract Location Russia Commence 2013 Completion -NA- Estimated Investment -NA- Capacity -NA- Key Players Rafarma Pharmaceuticals, Inc.

Other Projects